Nykode Therapeutics AS
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nykode Therapeutics AS
The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.
Regeneron is investing heavily to advance five vaccine programs with Nykode Therapeutics, the Norwegian company formerly known as Vaccibody.
The Israeli company raised $16m to support its Augmented Respiration Technology, a novel approach for delivering oxygen directly into the venous system. The company expects to earn FDA clearance for first product by 2023.
- Drug Delivery
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Norway OTC, Vaccibody
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.